Patent Foramen Ovale and Oxygenation in Patients with Cystic Fibrosis

Overview

Journal Respiration

Publisher Karger

Specialty Pulmonary Medicine

Date 2024 Oct 8

PMID 39378862

Authors

Haley Belt

Evbu O Enakpene

Judy L Jensen

Alice P Moe

Holly Carveth

Barbara C Cahill

Nathan Hatton

Theodore G Liou

Anwar Tandar

Affiliations

Soon will be listed here.

Abstract

Introduction: Patent foramen ovale (PFO) affects about 25% of the population. We studied outcomes in cystic fibrosis (CF).

Methods: We conducted a case-control study of patients with CF (PwCF) and age- and sex-matched controls who underwent agitated saline contrast (bubble) echocardiography, 1998-2020. We assessed PFO impacts using linear, logistic, quasi-Poisson, and Cox proportional hazards models.

Result: Fifty-nine of 64 PwCF and 88 of 93 controls underwent bubble studies to investigate unexplained hypoxemia or dyspnea. PwCF had higher mean pulmonary artery pressure (PAP: 6.9 mm Hg, 95% confidence interval [CI] = 2.35-11.4), reduced tricuspid annular plane systolic excursion (TAPSE: -3.78 mm, CI = -5.64 to -1.93) and similar right ventricular diastolic sizes. Without hypoxemia, the PFO incidence was similar between PwCF and controls; with hypoxemia, PFO was more common in CF (odds ratio = 5.00, CI = 1.32-19.0). In CF, oxygen supplementation occurred at a percent-predicted forced expiratory volume in 1 s (FEV1%), 22.5 points higher with PFO. Adjusted for FEV1%, PFO was associated with 0.59 more prior-year pulmonary exacerbations (CI = 0.20-0.98) and shorter time to next exacerbation (hazard ratio = 1.86, CI = 1.06-3.26). Associations between PFO and hypoxemia or exacerbations were insensitive to PAP, TAPSE, and CF transmembrane regulator protein modulator treatments. PFO was not associated with CF time to death or lung transplantation (median 1.87 years) adjusted for age, sex, FEV1%, and prior-year exacerbation counts.

Conclusion: PFO in CF is associated with hypoxemia at higher FEV1% and more pulmonary exacerbations but not survival.

References

Ilkhanoff L, Naidu S, Rohatgi S, Ross M, Silvestry F, Herrmann H . Transcatheter device closure of interatrial septal defects in patients with hypoxia. J Interv Cardiol. 2005; 18(4):227-32. DOI: 10.1111/j.1540-8183.2005.00043.x. View

Elborn J . Cystic fibrosis. Lancet. 2016; 388(10059):2519-2531. DOI: 10.1016/S0140-6736(16)00576-6. View

Epps Q, Epps K, Young D, Zobell J . State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary. Pediatr Pulmonol. 2021; 56(7):1825-1837. DOI: 10.1002/ppul.25353. View

Tobis J, Narasimha D, Abudayyeh I . Patent Foramen Ovale Closure for Hypoxemia. Interv Cardiol Clin. 2017; 6(4):547-554. DOI: 10.1016/j.iccl.2017.05.003. View

Ramsey B, Davies J, McElvaney N, Tullis E, Bell S, Drevinek P . A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365(18):1663-72. PMC: 3230303. DOI: 10.1056/NEJMoa1105185. View

Hagen P, Scholz D, Edwards W . Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984; 59(1):17-20. DOI: 10.1016/s0025-6196(12)60336-x. View

Ley S, Puderbach M, Fink C, Eichinger M, Plathow C, Teiner S . Assessment of hemodynamic changes in the systemic and pulmonary arterial circulation in patients with cystic fibrosis using phase-contrast MRI. Eur Radiol. 2005; 15(8):1575-80. DOI: 10.1007/s00330-005-2721-1. View

Kerem E, Wilschanski M, Miller N, Pugatsch T, Cohen T, Blau H . Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis. J Cyst Fibros. 2011; 10(3):193-200. DOI: 10.1016/j.jcf.2011.02.003. View

Farrell P, Rosenstein B, White T, Accurso F, Castellani C, Cutting G . Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008; 153(2):S4-S14. PMC: 2810958. DOI: 10.1016/j.jpeds.2008.05.005. View

10.

Liou T, Argel N, Asfour F, Brown P, Chatfield B, Cox D . Airway inflammation accelerates pulmonary exacerbations in cystic fibrosis. iScience. 2024; 27(3):108835. PMC: 10879674. DOI: 10.1016/j.isci.2024.108835. View

11.

Middleton P, Mall M, Drevinek P, Lands L, McKone E, Polineni D . Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019; 381(19):1809-1819. PMC: 7282384. DOI: 10.1056/NEJMoa1908639. View

12.

Keogh R, Tanner K, Simmonds N, Bilton D . The changing demography of the cystic fibrosis population: forecasting future numbers of adults in the UK. Sci Rep. 2020; 10(1):10660. PMC: 7327064. DOI: 10.1038/s41598-020-67353-3. View

13.

Kampelmacher M, van Kestern R, Alsbach G, Melissant C, Wynne H, Douze J . Characteristics and complaints of patients prescribed long-term oxygen therapy in The Netherlands. Respir Med. 1998; 92(1):70-5. DOI: 10.1016/s0954-6111(98)90035-x. View

14.

Fraser K, Tullis D, Sasson Z, Hyland R, Thornley K, Hanly P . Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Chest. 1999; 115(5):1321-8. DOI: 10.1378/chest.115.5.1321. View

15.

Simmonds N, Wyatt H, Patel R, Hodson M, Gyi K . A woman with cystic fibrosis, severe hypoxaemia, an atrial thrombus and a patent foramen ovale: a case report. J Med Case Rep. 2009; 3:8582. PMC: 2737785. DOI: 10.4076/1752-1947-3-8582. View

16.

Wainwright C, Elborn J, Ramsey B, Marigowda G, Huang X, Cipolli M . Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015; 373(3):220-31. PMC: 4764353. DOI: 10.1056/NEJMoa1409547. View

17.

Al Lawati N, Wilcox P . Paradoxical embolization in an adult cystic fibrosis patient. Can Respir J. 2007; 14(5):293-4. PMC: 2676396. DOI: 10.1155/2007/492128. View

18.

Giacchi V, Rotolo N, Amato B, Di Dio G, Betta P, La Rosa M . Heart involvement in children and adults with cystic fibrosis: correlation with pulmonary indexes and inflammation markers. Heart Lung Circ. 2015; 24(10):1002-10. DOI: 10.1016/j.hlc.2015.03.006. View

19.

Bright-Thomas R, Ray S, Webb A . Pulmonary artery pressure in cystic fibrosis adults: characteristics, clinical correlates and long-term follow-up. J Cyst Fibros. 2012; 11(6):532-8. DOI: 10.1016/j.jcf.2012.04.012. View

20.

Sondergaard L, Kasner S, Rhodes J, Andersen G, Iversen H, Nielsen-Kudsk J . Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017; 377(11):1033-1042. DOI: 10.1056/NEJMoa1707404. View